Back to Liraglutide research

Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review.


Summary withdrawn

TitrateLab removes an AI-written study summary when it states findings we cannot trace to the study's own record, or when the study falls outside the compounds we track. Read the original record through the link above.


liraglutide retatrutide semaglutide tirzepatide gip agonist glp 1 agonist glucagon agonist gip-r glp-1r dose mentioned protocol relevant safety data present
Source: pubmed:41025003 · Ingested Apr 3, 2026